- CytoDyn Inc. has appointed **Robert E. Hoffman** as its new **Chief Financial Officer**.  **[1175680_2fe04bb202364ac59dbb84017bc55664_0]** 
- The company is advancing **leronlimab** in oncology, with data presented at ESMO suggesting it induces **PD-L1 expression** in metastatic triple-negative breast cancer (mTNBC), potentially creating synergy with immune checkpoint inhibitors (ICIs).  **[1175680_2fe04bb202364ac59dbb84017bc55664_0]** 
- A follow-up **Phase II proof of concept protocol** for PD-L1-negative mTNBC patients will be submitted, proposing a regimen of leronlimab with standard chemotherapy, followed by leronlimab with an ICI.  **[1175680_2fe04bb202364ac59dbb84017bc55664_0]** 
- Pooled follow-up data from 28 mTNBC patients showed promising **overall survival rates** of **17.9% at both years 3 and 4**.  **[1175680_2fe04bb202364ac59dbb84017bc55664_4]** 
- CytoDyn is also progressing other clinical initiatives, including amendments to its colorectal cancer study, an advancing investigator-initiated glioblastoma study, and FDA/IRB approval for an Alzheimer's study.  **[1175680_2fe04bb202364ac59dbb84017bc55664_9]** **[1175680_2fe04bb202364ac59dbb84017bc55664_10]**

CytoDyn (CYDY)